BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 31438996)

  • 1. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
    Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
    PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
    Valero JG; Matas-Céspedes A; Arenas F; Rodriguez V; Carreras J; Serrat N; Guerrero-Hernández M; Yahiaoui A; Balagué O; Martin S; Capdevila C; Hernández L; Magnano L; Rivas-Delgado A; Tannheimer S; Cid MC; Campo E; López-Guillermo A; Colomer D; Pérez-Galán P
    Leukemia; 2021 Sep; 35(9):2635-2649. PubMed ID: 33731849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
    Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW
    Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
    Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
    Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
    Ao JY; Zhu XD; Chai ZT; Cai H; Zhang YY; Zhang KZ; Kong LQ; Zhang N; Ye BG; Ma DN; Sun HC
    Mol Cancer Ther; 2017 Aug; 16(8):1544-1554. PubMed ID: 28572167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity.
    Wiehagen KR; Girgis NM; Yamada DH; Smith AA; Chan SR; Grewal IS; Quigley M; Verona RI
    Cancer Immunol Res; 2017 Dec; 5(12):1109-1121. PubMed ID: 29097420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo.
    Chen CH; Liu YM; Pan SL; Liu YR; Liou JP; Yen Y
    Oncotarget; 2016 May; 7(18):26374-87. PubMed ID: 27029060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and Optimization of a Novel 2
    Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
    J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
    Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
    Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Grünewald S; Politz O; Bender S; Héroult M; Lustig K; Thuss U; Kneip C; Kopitz C; Zopf D; Collin MP; Boemer U; Ince S; Ellinghaus P; Mumberg D; Hess-Stumpp H; Ziegelbauer K
    Int J Cancer; 2019 Sep; 145(5):1346-1357. PubMed ID: 30807645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
    Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
    Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS-MAPK Reactivation Facilitates Acquired Resistance in
    Bockorny B; Rusan M; Chen W; Liao RG; Li Y; Piccioni F; Wang J; Tan L; Thorner AR; Li T; Zhang Y; Miao C; Ovesen T; Shapiro GI; Kwiatkowski DJ; Gray NS; Meyerson M; Hammerman PS; Bass AJ
    Mol Cancer Ther; 2018 Jul; 17(7):1526-1539. PubMed ID: 29654068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of FGF/FGFR pathway blocking on lung adenocarcinoma and its cancer-associated fibroblasts.
    Hegab AE; Ozaki M; Kameyama N; Gao J; Kagawa S; Yasuda H; Soejima K; Yin Y; Guzy RD; Nakamura Y; Ornitz DM; Betsuyaku T
    J Pathol; 2019 Oct; 249(2):193-205. PubMed ID: 31090071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
    Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
    Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.